Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ferrara

Showing results (111-120 of 143) with videos related to

Pageof 15
Sort By:
Lung Cancer (Amsterdam, Netherlands)|March 1, 2026
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testingFabrizio Citarella, Francesco M Venanzi, Giulia Di Giovanni, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.
Cancers|December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation CohortArsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2025
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experienceFrancesca Rita Ogliari, Alberto Traverso, Simone Barbieri, et al.
Clinical Lung Cancer|August 2, 2021
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon HistologySara Manglaviti, Marta Brambilla, Diego Signorelli, et al.
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Pageof 15

Showing results (111-120 of 143) with videos related to

Sort By:
Pageof 15
Lung Cancer (Amsterdam, Netherlands)|March 1, 2026
Family history enrichment in Non-Small cell Lung Cancer: A cross-sectional - prospective study to inform referral for germline testingFabrizio Citarella, Francesco M Venanzi, Giulia Di Giovanni, et al.
Clinical Lung Cancer|April 16, 2020
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External ValidationArsela Prelaj, Giuseppe Lo Russo, Claudia Proto, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2021
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkersRiccardo Lobefaro, Giuseppe Viscardi, Raimondo Di Liello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2019
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre studyW Victoria Lai, Louisiane Lebas, Tristan A Barnes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.
Cancers|December 11, 2019
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation CohortArsela Prelaj, Roberto Ferrara, Sara Elena Rebuzzi, et al.
Lung Cancer (Amsterdam, Netherlands)|January 3, 2025
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experienceFrancesca Rita Ogliari, Alberto Traverso, Simone Barbieri, et al.
Clinical Lung Cancer|August 2, 2021
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon HistologySara Manglaviti, Marta Brambilla, Diego Signorelli, et al.
Cancers|January 21, 2022
Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with ImmunotherapyArsela Prelaj, Mattia Boeri, Alessandro Robuschi, et al.
Pageof 15